» Articles » PMID: 28484033

Ectopic Protein Interactions Within BRD4-chromatin Complexes Drive Oncogenic Megadomain Formation in NUT Midline Carcinoma

Overview
Specialty Science
Date 2017 May 10
PMID 28484033
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

To investigate the mechanism that drives dramatic mistargeting of active chromatin in NUT midline carcinoma (NMC), we have identified protein interactions unique to the BRD4-NUT fusion oncoprotein compared with wild-type BRD4. Using cross-linking, affinity purification, and mass spectrometry, we identified the EP300 acetyltransferase as uniquely associated with BRD4 through the NUT fusion in both NMC and non-NMC cell types. We also discovered ZNF532 associated with BRD4-NUT in NMC patient cells but not detectable in 293T cells. EP300 and ZNF532 are both implicated in feed-forward regulatory loops leading to propagation of the oncogenic chromatin complex in BRD4-NUT patient cells. Adding key functional significance to our biochemical findings, we independently discovered a translocation fusion in a newly diagnosed NMC patient. ChIP sequencing of the major players NUT, ZNF532, BRD4, EP300, and H3K27ac revealed the formation of ZNF532-NUT-associated hyperacetylated megadomains, distinctly localized but otherwise analogous to those found in BRD4-NUT patient cells. Our results support a model in which NMC is dependent on ectopic NUT-mediated interactions between EP300 and components of BRD4 regulatory complexes, leading to a cascade of misregulation.

Citing Articles

Pulmonary Nuclear protein in Testis (NUT) carcinoma: clinical, molecular characteristics, and treatment strategies.

Qu J, Chen Z, Zhu Y, Huang J, Shen Q BMC Cancer. 2025; 25(1):196.

PMID: 39905380 PMC: 11792297. DOI: 10.1186/s12885-025-13593-3.


Adding checkpoint inhibitors to first-line chemotherapy for NUT carcinoma patients.

Haebe S, Schuebbe G, Jurmeister P, von Bergwelt-Baildon M, Westphalen C, Lauer U NPJ Precis Oncol. 2025; 9(1):26.

PMID: 39863772 PMC: 11762287. DOI: 10.1038/s41698-024-00768-7.


Catalytic-independent functions of the Integrator-PP2A complex (INTAC) confer sensitivity to BET inhibition.

Fan P, Shang X, Song A, Chen S, Mao R, Ma J Nat Chem Biol. 2025; .

PMID: 39809894 DOI: 10.1038/s41589-024-01807-x.


Clinical analysis and treatment progress of NUT carcinoma in the nasal cavity and sinuses: a retrospective study from a single institution.

Gao W, Feng L, Zhao X, Huang Z, Chen D, Yin G Eur Arch Otorhinolaryngol. 2024; 282(1):377-386.

PMID: 39154145 DOI: 10.1007/s00405-024-08898-1.


[Research Progress on Pathogenesis and Treatment of NUT Carcinoma].

Du J, Zhang X Zhongguo Fei Ai Za Zhi. 2024; 27(6):466-470.

PMID: 39026498 PMC: 11258642. DOI: 10.3779/j.issn.1009-3419.2024.101.16.


References
1.
Lin X, Huang X, Uziel T, Hessler P, Albert D, Roberts-Rapp L . HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues. Mol Cancer Ther. 2016; 16(2):388-396. DOI: 10.1158/1535-7163.MCT-16-0475. View

2.
Hein M, Hubner N, Poser I, Cox J, Nagaraj N, Toyoda Y . A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell. 2015; 163(3):712-23. DOI: 10.1016/j.cell.2015.09.053. View

3.
Dawson M, Prinjha R, Dittmann A, Giotopoulos G, Bantscheff M, Chan W . Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011; 478(7370):529-33. PMC: 3679520. DOI: 10.1038/nature10509. View

4.
Kharchenko P, Tolstorukov M, Park P . Design and analysis of ChIP-seq experiments for DNA-binding proteins. Nat Biotechnol. 2008; 26(12):1351-9. PMC: 2597701. DOI: 10.1038/nbt.1508. View

5.
Toretsky J, Jenson J, Sun C, Eskenazi A, Campbell A, Hunger S . Translocation (11;15;19): a highly specific chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients. Am J Clin Oncol. 2003; 26(3):300-6. DOI: 10.1097/01.COC.0000020960.98562.84. View